Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Caterpillar Inc (CAT) vs Ginkgo Bioworks Holdings Inc (DNA) Price & Performance

Caterpillar IncTrade
Ginkgo Bioworks Holdings IncTrade

Price performance (Past 24H)

Key statistics

Caterpillar Inc vs Ginkgo Bioworks Holdings Inc — how do they compare? Caterpillar Inc trades at $847.01 (market cap $385.01B), while Ginkgo Bioworks Holdings Inc trades at $7.54 (market cap $515.15M). The key difference: Caterpillar Inc is far larger — about 747.4× Ginkgo Bioworks Holdings Inc's market cap, and Caterpillar Inc pays a 0.78% dividend while Ginkgo Bioworks Holdings Inc pays none. Which is the better fit depends on your goals.

CATDNA
Market Cap
$385.01B$515.15M
Sector
IndustrialsHealth
52-Week High
$1.06K$16.14
52-Week Low
$407.79$5.48
Enterprise Value
$423.45B$617.10M
Dividend Yield
0.78%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Caterpillar Inc

Caterpillar (CAT) trades at $843.37, up 0.14% on the day, with strong year-to-date performance driven by robust earnings beats and AI data center demand. The stock shows a bearish technical signal but maintains solid fundamentals, including a net income margin of 14.51% and ROE of 56.99%. Recent news highlights growth from power and energy segments, with a dividend increase expected in June 2026.

Outlook remains positive due to earnings momentum and infrastructure tailwinds, though elevated valuation ratios like a P/E of 36.07 pose risks. Analyst consensus is bullish with a $1,010 price target, but investors should monitor economic cycles and competitive pressures that could impact future performance.

Ginkgo Bioworks Holdings Inc

Ginkgo Bioworks (DNA) trades at $7.97, down 6.24% today, reflecting ongoing operational challenges. The company reported Q2 2026 revenue of $20 million, a 48% year-over-year decline, as it shifts focus to autonomous lab systems. Despite beating EPS expectations in two of the last three quarters, net losses remain substantial with a -219.6% margin. Technical indicators show bearish momentum with support at $7 and resistance at $9.

DNA faces significant headwinds with declining revenue and persistent losses, though analyst sentiment is mixed with 45% buy ratings. The pivot to new business lines creates uncertainty, while cash burn and competitive pressures present substantial risks. Upside depends on successful execution of the strategic shift and path to profitability.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Caterpillar Inc

Caterpillar Inc. designs, manufactures, and markets construction, mining, and forestry machinery. The Company also manufactures engines and other related parts for its equipment, and offers financing and insurance. Caterpillar distributes its products through a worldwide organization of dealers.

Read more on CAT

About Ginkgo Bioworks Holdings Inc

Ginkgo Bioworks is a leading horizontal platform for cell programming. It uses advanced automation and software to design custom organisms for customers across diverse industries, including food, agriculture, and pharma.

Read more on DNA